19.94
전일 마감가:
$19.25
열려 있는:
$19.21
하루 거래량:
540.46K
Relative Volume:
0.32
시가총액:
$1.27B
수익:
-
순이익/손실:
$-107.85M
주가수익비율:
-9.0226
EPS:
-2.21
순현금흐름:
$-106.82M
1주 성능:
-3.68%
1개월 성능:
-12.82%
6개월 성능:
-44.59%
1년 성능:
-43.83%
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VERA
Vera Therapeutics Inc
|
19.94 | 1.32B | 0 | -107.85M | -106.82M | -2.21 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
385.12 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.18 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
432.06 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
670.25 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.19 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
베라 테라 Stock (VERA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-05 | 재개 | H.C. Wainwright | Buy |
2025-02-04 | 개시 | Wolfe Research | Outperform |
2025-01-28 | 개시 | Goldman | Buy |
2024-11-21 | 개시 | Wells Fargo | Overweight |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-01-25 | 개시 | Oppenheimer | Outperform |
2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
2023-12-18 | 개시 | Raymond James | Outperform |
2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
2023-08-16 | 개시 | Guggenheim | Buy |
2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
2022-07-12 | 개시 | JP Morgan | Overweight |
2022-05-02 | 개시 | H.C. Wainwright | Buy |
2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera (VERA) Q2 Net Loss Widens 127% - The Motley Fool
Vera Therapeutics Reports Progress in Clinical Trials - TipRanks
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $60 to $85 - 富途牛牛
Vera Therapeutics Signs New Sales Agreement with TD Securities - TipRanks
Form 424B5 Vera Therapeutics, Inc. - StreetInsider
Vera Therapeutics sees cash funding operations through launch of atacicept - TipRanks
Vera Therapeutics reports Q2 EPS ($1.20), consensus (62c) - TipRanks
Vera Therapeutics announces anticipated upcoming milestones - TipRanks
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Manila Times
Trendlines Converge — Decision Point for Vera Therapeutics Inc.Momentum Based Equity Trading Plans Reviewed - metal.it
Wolfe Research downgrades Vera Therapeutics stock rating on limited catalysts - Investing.com Canada
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research - TipRanks
Vera Therapeutics Inc.’s Price Action Aligns with Quant SignalsFast Exit and Entry Strategy Guide Offered - metal.it
How volatile is Vera Therapeutics Inc. stock compared to the marketAchieve breakthrough financial results today - Jammu Links News
Is Vera Therapeutics Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
Is Vera Therapeutics Inc. a good long term investmentAchieve breakthrough profits with expert advice - Jammu Links News
How strong is Vera Therapeutics Inc. company’s balance sheetPowerful profit generation - Jammu Links News
What are the latest earnings results for Vera Therapeutics Inc.Breakthrough wealth creation - Jammu Links News
Vera Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough performance with smart picks - Jammu Links News
What is the dividend policy of Vera Therapeutics Inc. stockBuild your wealth with consistent stock growth - Jammu Links News
What catalysts could drive Vera Therapeutics Inc. stock higher in 2025Discover breakthrough stocks before the crowd - Jammu Links News
What are Vera Therapeutics Inc. company’s key revenue driversStay ahead with daily expert stock picks - Jammu Links News
Does Vera Therapeutics Inc. stock perform well during market downturnsUnlock exclusive trading strategies - Jammu Links News
What is Vera Therapeutics Inc. company’s growth strategyFree Real-Time Stock Data - Jammu Links News
What are the technical indicators suggesting about Vera Therapeutics Inc.Free Buy/Sell Signal Notifications - Jammu Links News
Short Interest Drops in Vera Therapeutics Inc. After RallyCommunity Strategy With High Win Rate Backtested - metal.it
Top Risks to Consider Before Buying Vera Therapeutics Inc. StockHigh Conviction Intraday Stock Signals Detected - metal.it
Published on: 2025-07-30 16:01:27 - metal.it
Can Vera Therapeutics Inc. stock recover from recent declineWeekly Hot Picks With Buy Confidence Released - beatles.ru
Why is Vera Therapeutics Inc. stock attracting strong analyst attentionSwing Trade Report To Watch Now - Jammu Links News
What are analysts’ price targets for Vera Therapeutics Inc. in the next 12 monthsCapitalize on market trends before they peak - Jammu Links News
Will Vera Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Stock Investment Discussion Area - metal.it
Behind The Volatility Of Vera Therapeutics (NASDAQ:VERA) - Seeking Alpha
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
자본화:
|
볼륨(24시간):